INTENSIVE BLOOD PRESSURE LOWERING WITH AZILSARTAN IN INDIAN HYPERTENSIVE PATIENTS IN REAL-WORLD CLINICAL SETTINGS: INTENSE STUDY
Dr. N. P. Rao*, Dr. Gita Nadimpalli and Dr. Shahu Ingole
Background: Hypertension (HTN) is ranked as third most important risk factor for attributable burden of cardiovascular disease. Azilsartan, because of highest responder rate, appears to be the most suited antihypertensive agent to achieve the target blood pressure (BP). As there is limited Indian clinical trial data and real-world studies on safety and effectiveness of azilsartan, this study was designed to investigate the â€˜real-worldâ€™ effectiveness and safety of azilsartan in Indian hypertensive patients associated with various co-morbidities. Methods: This was a prospective, non-interventional, real-world study of Indian adult patients of diagnosed with essential HTN and prescribed with tablet azilsartan. Demographic data, details of treatment with azilsartan, changes in BP and occurrence of adverse events (AE) were noted during the follow-up visits (6 and 12 weeks). Results: Among 240 enrolled patients, mean reduction systolic BP from baseline with azilsartan was 16.2+11.1 mm Hg and 27.16+10.6 mm Hg (p<0.001) at Week 6 and Week 12 respectively. The proportion of patients achieving target systolic BP of â‰¤140 mm Hg was 56.70% at Week 12. The proportion of patients achieving aggressive target BP of <130/80 mm Hg was 40.42% at Week 12. In patients uncontrolled on telmisartan and shifted to azilsartan, the proportion of patients with target systolic BP of â‰¤140 mm Hg at Week 12 was 75%. Conclusion: The results of present real-world study suggest that azilsartan is effective and safe in the treatment of newly diagnosed treatment-naÃ¯ve hypertensive patients as well as those uncontrolled on other antihypertensive agents including telmisartan with associated co-morbidities.
Keywords: Hypertension, azilsartan, blood pressure, telmisartan.
[Full Text Article]